Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hubertus Hautzel

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2024
Diagnostic Accuracy of <sup>68</sup>Ga-FAPI Versus <sup>18</sup>F-FDG PET in Patients with Various MalignanciesNader Hirmas, Rainer Hamacher, Miriam Sraieb, et al.
Translational Lung Cancer Research|July 17, 2025
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitisAndreas Herz, Maja Guberina, Christoph Pöttgen, et al.
Diagnostics (Basel, Switzerland)|March 28, 2026
Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLCAndreas Herz, Aymane Khouya, Maja Guberina, et al.
European Journal of Cancer (Oxford, England : 1990)|February 17, 2026
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysisWilfried Ernst Erich Eberhardt, Christina Schulte, Christoph Pöttgen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 2022
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Rainer Hamacher, Miriam Sraieb, et al.
Thoracic Cancer|November 20, 2025
Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung CancerMaja Guberina, Martin Metzenmacher, Christoph Pöttgen, et al.
Hematological Oncology|February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialChristine Schmitz, Jan Rekowski, Stefan P Müller, et al.
Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2024
Diagnostic Accuracy of <sup>68</sup>Ga-FAPI Versus <sup>18</sup>F-FDG PET in Patients with Various MalignanciesNader Hirmas, Rainer Hamacher, Miriam Sraieb, et al.
Translational Lung Cancer Research|July 17, 2025
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitisAndreas Herz, Maja Guberina, Christoph Pöttgen, et al.
Diagnostics (Basel, Switzerland)|March 28, 2026
Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLCAndreas Herz, Aymane Khouya, Maja Guberina, et al.
European Journal of Cancer (Oxford, England : 1990)|February 17, 2026
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysisWilfried Ernst Erich Eberhardt, Christina Schulte, Christoph Pöttgen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 2022
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Rainer Hamacher, Miriam Sraieb, et al.
Thoracic Cancer|November 20, 2025
Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung CancerMaja Guberina, Martin Metzenmacher, Christoph Pöttgen, et al.
Hematological Oncology|February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialChristine Schmitz, Jan Rekowski, Stefan P Müller, et al.
Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
Pageof 11